Propofol reduces the distribution and clearance of midazolam

Anesthesia and Analgesia

Volumn 110, Issue 6, 2010, Pages 1597-1606

  Lichtenbelt, Bart Jan ^a   Olofsen, Erik ^b   Dahan, Albert ^b   Van Kleef, Jack W ^b   Struys, Michel M ^a   Vuyk, Jaap ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MIDAZOLAM; PROPOFOL;

ABSENCE OF SIDE EFFECTS; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMPUTER SIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEMODYNAMIC PARAMETERS; HUMAN; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE;

ADULT; ALGORITHMS; ANESTHETICS, INTRAVENOUS; COMPUTER SIMULATION; CROSS-OVER STUDIES; DRUG INTERACTIONS; HEMODYNAMICS; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MODELS, STATISTICAL; NONLINEAR DYNAMICS; PROPOFOL; TISSUE DISTRIBUTION;

EID: 77953212607     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181da91bb     Document Type: Article

References (36)

1. Vuyk J, Lichtenbelt BJ, Olofsen E, van Kleef JW, Dahan A. Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. Anesth Analg 2009;108:1522-1530
2. Oxorn DC, Ferris LE, Harrington E, Orser BA. The effects of midazolam on propofol-induced anesthesia: propofol dose requirements, mood profiles, and perioperative dreams. Anesth Analg 1997;85:553-559
3. Short TG, Chui PT. Propofol and midazolam act synergistically in combination. Br J Anaesth 1991;67:539-545
4. Short TG, Plummer JL, Chui PT. Hypnotic and anaesthetic interactions between midazolam, propofol and alfentanil. Br J Anaesth 1992;69:162-167
5. Gonzalez-Arrieta ML, Juarez MJ, Silva HJ, Galindo FA, Labastida S, Campos A, Jimenez VM. Total intravenous anesthesia with propofol vs. propofol/midazolam in oncology patients. Arch Med Res 1995;26:75-78
6. Lichtenbelt BJ, Mertens M, Vuyk J. Strategies to optimise propofol-opioid anaesthesia. Clin Pharmacokinet 2004;43:577-593
7. Vuyk J. The effect of opioids on the pharmacokinetics and pharmacodynamics of propofol. In: Vuyk J, Englbers F, Groen- Mulder S, eds. On the Study and Practice of Intravenous Anaesthesia. London: Kluwer Academic Publishers, 2000:99-111
8. Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. Clin Pharmacol Ther 1999;66:110-117
9. Jacobs JR, Reves JG, Marty J, White WD, Bai SA, Smith LR. Aging increases pharmacodynamic sensitivity to the hypnotic effects of midazolam. Anesth Analg 1995;80:143-148
10. Carrasco G, Cabre L, Sobrepere G, Costa J, Molina R, Cruspinera A, Lacasa C. Synergistic sedation with propofol and midazolam in intensive care patients after coronary artery bypass grafting. Crit Care Med 1998;26:844-851
11. McClune S, McKay AC, Wright PM, Patterson CC, Clarke RS. Synergistic interaction between midazolam and propofol. Br J Anaesth 1992;69:240-245
12. Hamilton TT, Huber LM, Jessen ME. PulseCO: a less-invasive method to monitor cardiac output from arterial pressure after cardiac surgery. Ann Thorac Surg 2002;74:S1408-12
13. Vletter AA, Burm AG, Breimer LT, Spierdijk J. Highperformance liquid chromatographic assay to determine midazolam and flumazenil simultaneously in human plasma. J Chromatogr 1990;530:177-185
14. Kuipers JA, Boer F, Olieman W, Burm AG, Bovill JG. First-pass lung uptake and pulmonary clearance of propofol: assessment with a recirculatory indocyanine green pharmacokinetic model. Anesthesiology 1999;91:1780-1787
15. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;AC-19:716-723
16. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Monographs on Statistics and Applied Probability. New York: Chapman & Hall/CRC, 1993
17. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997;37:486-495
18. Zomorodi K, Donner A, Somma J, Barr J, Sladen R, Ramsay J, Geller E, Shafer SL. Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. Anesthesiology 1998;89:1418-1429
19. Bührer M, Maitre PO, Crevoisier C, Stanski DR. Electroencephalographic effects of benzodiazepines. II. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. Clin Pharmacol Ther 1990;48:555-567
20. Maitre PO, Funk B, Crevoisier C, Ha HR. Pharmacokinetics of midazolam in patients recovering from cardiac surgery. Eur J Clin Pharmacol 1989;37:161-166
21. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984;61:27-35
22. Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 2007;82:410-426
23. Rogers JF, Rocci ML, Haughey DB, Bertino JS. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 2003;73:153-158
24. Rogers JF, Morrison AL, Nafziger AN, Miller MT, Jones CL, Bertino JS. Flumazenil pretreatment minimizes midazolaminduced central nervous system (CNS) effects during hepatic CYP3A phenotyping in healthy subjects. Clin Pharmacol Ther 2002;71:86
25. Mc Donnell CG, Shorten G, Van Pelt FN. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia 2005;60:747-753
26. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42:819-850
27. Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 2003;17:513-532
28. Zhou S, Yung CS, Cher GB, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44: 279-304
29. Mertens MJ, Olofsen E, Burm AGL, Bovill JG, Vuyk J. Mixedeffects modeling of the influence of alfentanil on propofol pharmacokinetics. Anesthesiology 2004;100:795-805
30. Mertens MJ, Vuyk J, Olofsen E, Bovill JG, Burm AG. Propofol alters the pharmacokinetics of alfentanil in healthy male volunteers. Anesthesiology 2001;94:949-957
31. Bouillon T, Bruhn J, Radu-Radulescu L, Bertaccini E, Park S, Shafer S. Non-steady state analysis of the pharmacokinetic interaction between propofol and remifentanil. Anesthesiology 2002;97:1350-1362
32. Lange H, Stephan H, Rieke H, Kellermann M, Sonntag H, Bircher J. Hepatic and extrahepatic disposition of propofol in patients undergoing coronary-bypass surgery. Br J Anaesth 1990;64:563-570
33. Leslie K, Sessler DI, Bjorksten AR, Moayeri A. Mild hypothermia alters propofol pharmacokinetics and increases the duration of action of atracurium. Anesth Analg 1995;80:1007-1014
34. Yang LQ, Yu WF, Cao YF, Gong B, Chang Q, Yang GS. Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes. World J Gastroenterol 2003;9:1959-1962
35. Steyerberg EW. Clinical Prediction Models. A Practical Approach to Development, Validation and Updating (Statistics for Biology and Health). New York: Springer, 2009:193-194
36. Reinhart DJ, Grum DR, Berry J, Lensch D, Marchbanks CR, Zsigmond E. Outpatient general anesthesia: a comparison of a combination of midazolam plus propofol and propofol alone. J Clin Anesth 1997;9:130-137